Key Points
- EVP Steven Stein sold 2,559 Incyte shares at an average of $102.96 for $263,474.64, leaving him with 100,327 shares (a 2.49% reduction) valued at about $10.33 million.
- Incyte beat Q3 expectations with EPS of $2.26 vs. $1.65 consensus and revenue of $1.37 billion, up 20% year‑over‑year.
- The stock carries a market cap near $19.93 billion and a 52‑week range of $53.56–$109.28, with a MarketBeat consensus rating of Hold and a $93.85 price target (7 Buy / 11 Hold / 1 Sell).
Incyte Corporation (NASDAQ:INCY - Get Free Report) EVP Steven Stein sold 2,559 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $102.96, for a total value of $263,474.64. Following the transaction, the executive vice president owned 100,327 shares of the company's stock, valued at $10,329,667.92. The trade was a 2.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Incyte Trading Up 0.1%
Shares of Incyte stock opened at $101.50 on Thursday. The stock has a market capitalization of $19.93 billion, a P/E ratio of 17.00, a P/E/G ratio of 0.70 and a beta of 0.81. Incyte Corporation has a 52-week low of $53.56 and a 52-week high of $109.28. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.20. The stock's 50-day simple moving average is $95.14 and its 200 day simple moving average is $81.97.
Incyte (NASDAQ:INCY - Get Free Report) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $2.26 earnings per share for the quarter, topping the consensus estimate of $1.65 by $0.61. Incyte had a net margin of 24.69% and a return on equity of 26.56%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same quarter last year, the company earned $1.07 earnings per share. The company's revenue was up 20.0% on a year-over-year basis. As a group, research analysts anticipate that Incyte Corporation will post 4.86 EPS for the current year.
Hedge Funds Weigh In On Incyte
Hedge funds and other institutional investors have recently modified their holdings of the company. Allworth Financial LP raised its holdings in shares of Incyte by 107.1% during the 3rd quarter. Allworth Financial LP now owns 3,564 shares of the biopharmaceutical company's stock valued at $302,000 after buying an additional 1,843 shares in the last quarter. Swiss Life Asset Management Ltd grew its position in Incyte by 180.8% during the third quarter. Swiss Life Asset Management Ltd now owns 85,480 shares of the biopharmaceutical company's stock valued at $7,250,000 after acquiring an additional 55,039 shares during the last quarter. Groupama Asset Managment raised its stake in shares of Incyte by 1.4% during the third quarter. Groupama Asset Managment now owns 73,075 shares of the biopharmaceutical company's stock worth $6,197,000 after acquiring an additional 987 shares in the last quarter. CIBC Private Wealth Group LLC lifted its holdings in shares of Incyte by 153.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 726 shares of the biopharmaceutical company's stock worth $62,000 after acquiring an additional 440 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Incyte in the 3rd quarter valued at $1,921,000. 96.97% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages have issued reports on INCY. Wall Street Zen raised shares of Incyte from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 1st. Wells Fargo & Company lifted their price target on Incyte from $89.00 to $97.00 and gave the company an "overweight" rating in a research report on Wednesday, October 29th. Barclays increased their price objective on Incyte from $101.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, November 24th. JPMorgan Chase & Co. lifted their target price on Incyte from $73.00 to $89.00 and gave the company a "neutral" rating in a report on Thursday, October 9th. Finally, Bank of America increased their price target on shares of Incyte from $90.00 to $104.00 and gave the stock a "buy" rating in a report on Thursday, September 4th. Seven research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $93.85.
View Our Latest Stock Analysis on Incyte
Incyte Company Profile
(
Get Free Report)
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
